A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.
Lynn Mara Schuchter
Research Funding - Roche
Lawrence E. Flaherty
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
Omid Hamid
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Gerald P. Linette
Honoraria - Bristol-Myers Squibb; Genentech; GlaxoSmithKline
Sigrun Hallmeyer
No relevant relationships to disclose
Rene Gonzalez
Consultant or Advisory Role - Roche
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
Charles Lance Cowey
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Eisai; Genentech; GlaxoSmithKline; Novartis
Anna C. Pavlick
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Fred J. Kudrik
No relevant relationships to disclose
David H. Lawson
Consultant or Advisory Role - Roche
Kim Allyson Margolin
Honoraria - Roche/Genentech
Antoni Ribas
Consultant or Advisory Role - Roche/Genentech
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Prometheus
James L. Khatcheressian
No relevant relationships to disclose
Keith T. Flaherty
Consultant or Advisory Role - Roche/Genentech
Bann-Mo Day
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Rolf Gerhard Linke
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
John D. Hainsworth
No relevant relationships to disclose